With the continuous emergence of innovative achievements, pharmaceutical companies' innovative drug revenue growth rate is strong

[Pharmaceutical Network Industry News] With the acceleration of new drug approval and review, the advancement of medical insurance policies, and the gradual improvement of the innovative drug policy system, China's innovative drug industry has developed rapidly, new drug products are constantly being launched, and the market is also expanding
.

Data show that in 2018, the scale of China's innovative drug market has exceeded 100 billion yuan, and it is expected to reach 250 billion yuan by 2023
.

It is worth mentioning that in the context of the continuous launch of innovative drugs, the growth rate of a large number of drug revenues is also very strong, which has brought benefits to many pharmaceutical companies
.

Recently, Hansoh Pharma announced its 2021 annual results
.

In 2021, revenue was 9.
935 billion yuan, a year-on-year increase of 14.
3%; profit was 2.
713 billion yuan, a year-on-year increase of 5.
6%; R&D investment was 1.
797 billion yuan, a year-on-year increase of 43.
5%, accounting for 18.
1% of revenue
.

Among them, the sales revenue of innovative drugs of Hansoh Pharma in 2021 will reach 4.
202 billion yuan, a year-on-year increase of 168.
9%, and the proportion of revenue will increase from 18.
0% in 2020 to 42.
3%
.

 　　It is understood that the revenue of innovative drugs includes the total revenue of five products: Ametinib (Amelox), Flumatinib (Hosein Xinfu), Morinidazole (Melinda), Loxenatide (Fulai) The United States) and tenofovir (Hengmu), these five products have now entered the medical insurance category B catalog
.

 　　In addition to Hansoh Pharma, there are some companies that have continued to expand their investment in innovative drug research and development, and now they have begun to accelerate the realization of innovative results
.

For example, in 2021, the revenue of Fosun Pharma's pharmaceutical segment will increase by 32.
1% year-on-year to 28.
904 billion yuan, accounting for 74.
1%
.

 　　Among them, the company's revenue in the pharmaceutical sector has increased significantly, mainly including Fubitai, Hanlikang, Hanquyou, Su Kexin, etc.
The revenue of new products and sub-new products accounted for more than 25% of the revenue of the pharmaceutical business, and the revenue structure has been sustained.
optimization
.

It is worth mentioning that during the reporting period, its self-developed product Hanlikang (rituximab injection) achieved revenue of 1.
690 billion yuan, a year-on-year increase of 125.
33%
.

 　　In addition, Simcere also stated in its 2021 performance report that the transformation to innovation has achieved remarkable results
.

Among them, innovative drug revenue has become the main source of revenue of the Group, with approximately RMB 3.
120 billion, an increase of approximately 53.
8% compared with the innovative drug revenue of RMB 2.
029 billion in the same period in 2020, with a strong growth rate
.

The proportion of innovative drug revenue to total revenue during the same period also reached a record high of 62.
4% (32.
9% in 2019 and 45.
1% in 2020)
.

 　　The announcement shows that the increase in Simcere’s total revenue in 2021 is mainly due to the rapid growth in revenue brought by the innovative drug Xianbixin® (Edaravone Dexbornol Injection Concentrated Solution)
.

 　　In general, the continuous emergence of innovative results is bringing benefits to a large number of pharmaceutical companies
.

In the future, with the orderly advancement of the R&D and commercialization of innovative products of pharmaceutical companies, the industry expects that there are still a large number of pharmaceutical companies whose intrinsic potential will gradually wake up and usher in further sales growth
.

 　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone